New Hampshire House Bill HB130

New Hampshire 2024 Regular Session

• Introduced: 12/23/22
• Refer: 12/23/22
• Refer: 1/24/23
• Report DNP: 11/16/23

Caption

Repealing the drug affordability board.

Impact

The elimination of the drug affordability board would impact laws related to prescription drug pricing in New Hampshire. Previously, the board was tasked with creating mechanisms intended to manage and monitor drug costs. Its repeal may lead to higher drug prices for consumers, as there would be no state-level body focused on affordability. This could affect both individual residents and healthcare providers who rely on affordable medication options for their patients.

Summary

House Bill 130 aims to repeal the New Hampshire drug affordability board and the associated fund that supports its administration. The drug affordability board was established to oversee and regulate prescription drug prices, making them more accessible and affordable for residents. By eliminating this board, the bill suggests a significant shift in the state's approach to managing drug costs. This repeal is indicative of a broader legislative trend towards reducing government oversight in healthcare pricing practices.

Contention

Supporters of HB 130 argue that the removal of the drug affordability board will reduce bureaucratic overhead and encourage a more market-driven approach to drug pricing. They contend that competition among private entities might lead to better pricing dynamics. However, opponents raise the concern that this decision could result in unchecked drug prices, potentially making essential medications unaffordable for many citizens. Critics highlight that without a mechanism to regulate prices, vulnerable populations could suffer significantly.